One other stock of interest is VistaGen (VTGN), which should be fun to watch over the next period of months as they release key data from two clinical trials. The chart has been weak, and so far no 'runup ahead of the binary event'.
The upside is huge, and it would be great to see their drug work, though the odds appear slim. Best to watch this one from the sidelines, but biotech is full of surprises..